SCG Investments

SCG Cell Therapy is a clinical-stage biopharmaceutical company headquartered in Singapore, focusing on the development of novel immunotherapies for infections and their associated cancers. The company leverages its proprietary GianT TCR discovery platform and CAST cell manufacturing technology to create a pipeline of T-cell receptor (TCR) T-cell therapies, antibodies, and therapeutic vaccines. Its lead candidate, SCG101, is an autologous HBV-specific TCR-T cell therapy currently in Phase 1/2 clinical trials for HBV-related hepatocellular carcinoma. SCG's portfolio also includes programs targeting HPV-associated tumors and H. pylori-induced gastric cancer, aiming to provide curative treatments for high-prevalence diseases in Asia and globally.